[HTML][HTML] New-onset movement disorders associated with COVID-19
Methods: We reviewed the scientific literature published in English, spanning from the initial
descriptions of COVID-19 until January 25, 2021, in the PubMed/MEDLINE database …
descriptions of COVID-19 until January 25, 2021, in the PubMed/MEDLINE database …
Disaster management of the psychological impact of the COVID-19 pandemic
M Sheek-Hussein, FM Abu-Zidan, E Stip - International journal of …, 2021 - Springer
Background The COVID-19 pandemic has exposed a suboptimal response to this
threatening global disaster, including the response to the psychological impact. Both the …
threatening global disaster, including the response to the psychological impact. Both the …
Relationship between COVID‐19 and movement disorders: A narrative review
SA Schneider, A Hennig… - European Journal of …, 2022 - Wiley Online Library
Background and purpose The scientific literature on COVID‐19 is increasingly growing.
Methods In this paper, we review the literature on movement disorders in the context of the …
Methods In this paper, we review the literature on movement disorders in the context of the …
Neurological complications of COVID‐19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic
S Portela‐Sánchez… - European Journal of …, 2021 - Wiley Online Library
Objective To describe the spectrum of neurological complications observed in a hospital‐
based cohort of COVID‐19 patients who required a neurological assessment. Methods We …
based cohort of COVID‐19 patients who required a neurological assessment. Methods We …
COVID19-associated new-onset movement disorders: a follow-up study
SA Schneider, S Desai, O Phokaewvarangkul… - Journal of …, 2023 - Springer
Background Neurological symptoms are common manifestation in acute COVID-19. This
includes hyper-and hypokinetic movement disorders. Data on their outcome, however, is …
includes hyper-and hypokinetic movement disorders. Data on their outcome, however, is …
Safety profile of COVID-19 drugs in a real clinical setting
MN Chiu, M Bhardwaj, SP Sah - European journal of clinical pharmacology, 2022 - Springer
Purpose The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) virus has affected millions all over the world and has …
syndrome coronavirus 2 (SARS-CoV-2) virus has affected millions all over the world and has …
Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
The absence of a specific treatment for SARS-CoV-2 infection led to an intense global effort
in order to find new therapeutic interventions and improve patient outcomes. One important …
in order to find new therapeutic interventions and improve patient outcomes. One important …
De novo movement disorders and COVID‐19: exploring the Interface
R Ghosh, U Biswas, D Roy, A Pandit… - Movement Disorders …, 2021 - Wiley Online Library
Background Neurological manifestations of severe acute respiratory syndrome coronavirus
2 (SARS‐CoV‐2) are being widely documented. However, movement disorders in the …
2 (SARS‐CoV‐2) are being widely documented. However, movement disorders in the …
[HTML][HTML] Toxicity of psychotropic drugs in patients with COVID-19: a systematic review
Objective Due to the global spread of severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2), guidance for the use of psychotropic drugs in this context is necessary. We …
(SARS-CoV-2), guidance for the use of psychotropic drugs in this context is necessary. We …
Clinically significant drug interactions between psychotropic agents and repurposed COVID-19 therapies
As many patients with underlying psychiatric disorders may be infected with COVID-19, and
COVID-19-affected subjects may frequently experience a new onset of psychiatric …
COVID-19-affected subjects may frequently experience a new onset of psychiatric …